This is a Phase 3 study to assess the efficacy, safety, and tolerability of Baxdrostat on renal outcomes and cardiovascular events in CKD and Hypertension patients. The study will compare Baxdrostat in combination with Dapaglifozin, compared with Dapaglifozin alone. Participants must be at least 18 years old with a diagnosis of CKD and Hypertension.